Endpoints
The primary endpoint of the trial was to analyse the effect of 3 months treatment with empagliflozin on change in tissue (skin, muscle, bone marrow) sodium content compared to placebo. Secondary endpoints were the effect of 1 month treatment with empagliflozin on change in tissue sodium content compared to placebo as well as the effect of 1 and 3 months treatment with empagliflozin compared to baseline.